Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.

@article{Pignata2000PhaseIS,
  title={Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.},
  author={Sandro Pignata and Pasquale Frezza and Simona Tramontana and Francesco Perrone and Rosa Tambaro and Gennaro Casella and Ettore Ferrari and Francesco Iodice and Rocco De Vivo and Paolo Ricchi and Filippo Tramontana and Giustino Silvestro},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 4},
  pages={
          455-9
        }
}
BACKGROUND Cisplatin and paclitaxel are active in cervical cancer and both are able to potentiate the effects of radiotherapy. In this study we evaluated the maximum-tolerated dose (MTD) of paclitaxel in combination with a fixed dose of cisplatin when given weekly concurrently with pelvic radiotherapy to patients with carcinoma of the cervix uteri. PATIENTS AND METHODS Eighteen patients with cervical cancer were enrolled in this study. Cisplatin (30 mg/m2) and paclitaxel (starting dose 40 mg… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Similar Papers

Loading similar papers…